- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00705640
Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)
A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
Study Overview
Status
Detailed Description
OBJECTIVES:
- To assess the circulating CD8 T-cell response to vaccination with a multipeptide vaccine in patients with advanced melanoma.
- To determine whether immunization with peptides and incomplete Freund's adjuvant induces lymph-node-like aggregates (LNLA) and tertiary lymphoid organs (TLOs) in the skin of these patients.
- To determine whether extended immunization (vaccinations 4-6) is associated with induction of negative immune-regulatory processes in the vaccination site microenvironment/TLO.
- To characterize peptide-reactive CD4 and CD8 T cells in loco at sites of immunization with a multipeptide vaccine.
- To characterize the expression of toll-like receptors 4, 7, 8, and 9, and MyD88 in dendritic cells infiltrating vaccination sites over the course of 6 vaccinations and after vaccination.
OUTLINE: Patients are randomized to 1 of 10 arms.
All patients receive primary vaccine comprising melanoma multipeptides and tetanus toxoid helper peptide emulsified in incomplete Freund's adjuvant, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Vaccines are administered in a single skin location on an extremity clinically uninvolved with melanoma. A replicate vaccine site is identified for each patient for skin biopsy with or with out replica vaccine administration.
- Arm 1A: Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
- Arm 1B: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
- Arm 1C: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
- Arm 1D: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
- Arm 1E: Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
- Arm 2A: Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
- Arm 2B: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
- Arm 2C: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
- Arm 2D: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
- Arm 2E: Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
Tissue biopsies are examined by reverse transcriptase-PCR, IHC, protein analysis, flow cytometry, and western blot. Blood samples are collected periodically and examined by ELIspot assay, tetramer staining, and proliferation assay.
After completion of study therapy, patients are followed annually.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed melanoma that meets one of the following criteria:
- Stage IIB-IV melanoma rendered clinically free of disease by surgery, other therapy, or spontaneous remission within the past 6 months
- Stage III or IV melanoma with disease
- Persistent or metastatic disease allowed if RECIST criteria for measurable disease is not met
- Multiple primary melanomas allowed
- Prior or concurrent metastasis from a cutaneous, mucosal, ocular, or unknown primary site allowed
- No clinically detectable melanoma deemed likely by the investigator to require intervention during the first 12 weeks of the study that would require premature discontinuation (e.g., untreated bone metastases at risk for fracture or rapidly progressive low-volume disease)
Brain metastases allowed if all of the following criteria are met:
- The total number of brain metastases ever is ≤ 3
- The brain metastases have been completely removed by surgery or have been treated completely by stereotactic radiotherapy
- There has been no evident growth of any brain metastasis since treatment
- No treated brain metastasis > 2 cm in diameter
- At least two intact axillary and/or inguinal lymph node basins
Prior lymph node biopsy allowed if lymphoscintigraphy demonstrates intact drainage to a node in that basin
- If a sentinal lymph node is not located by lymphoscintigraphy, patient is not eligible for study
- HLA-A1, -A2, -A3, or -A11 positive
Either eligible for, but refused interferon therapy OR not a candidate for interferon therapy for the following reasons:
- Active ischemic heart disease or cerebrovascular disease
- Anginal syndrome requiring ongoing medications or history of myocardial infarction or arrhythmia disorder
- History of treatment for depression, active depression, or other psychiatric disorder
- Autoimmune disorders
- Hypersensitivity to interferon-alfa or any component associated with interferon therapy
- Debilitating medical conditions such as severe pulmonary disease or severe diabetes mellitus
- Thyroid abnormalities, where thyroid function cannot be maintained in the normal range without medication
- Resected stage IV melanoma
- Discontinued interferon therapy due to the occurrence of a major toxicity that has been documented by the treating physician
- Experienced tumor progression while on interferon or after completing interferon therapy
- Missed the standard-of-care enrollment window for interferon therapy initiation
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- ANC > 1,000/mm^3
- Platelets > 100,000/mm^3
- Hemoglobin > 9 g/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN
- Hepatitis C and HIV negative (antibody screening)
- Hemoglobin_A1C level < 7%
- Body weight ≥ 110 pounds
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during study treatment
- No New York Heart Association class III-IV heart disease
- No known or suspected allergies to any component of the vaccine
- No medical contraindication or potential problem in complying with the requirements of the protocol
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior peptide vaccines (including MELITAC 12.1 and similar vaccines) or non-peptide vaccines allowed
- At least 1 week since prior stereotactic radiotherapy, such as gamma knife
- No influenza vaccine ≥ 2 weeks before, during, and ≥ 2 weeks after completion of study therapy
More than 4 weeks since prior and no concurrent use of any of the following:
- Systemic cytotoxic chemotherapy (6 weeks for nitrosoureas)
- Radiotherapy
- Other experimental therapy
- Agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents and topical steroids)
- Allergy desensitization injections
- Systemic corticosteroids, administered parenterally or orally
Inhaled steroids (e.g., fluticasone propionate [Advair® or Flovent®] or triamcinolone acetonide [Azmacort®])
- Topical corticosteroids and steroids with very low solubility administered nasally for local effects only allowed (e.g., mometasone furoate [Nasonex®])
- Growth factors (e.g., sargramostim [GM-CSF], filgrastim [G-CSF], or epoetin alfa)
- Interferon therapy
- Aldesleukin or other interleukins
- Street drugs
- At least 1 month since prior and no other concurrent investigational drugs or therapy
- At least 12 weeks since prior melanoma vaccine for patients who have recurred or progressed either after or during treatment with vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1A
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive no replicate vaccine.
Patients undergo surgical biopsy at replicate vaccine site on day 1.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 1B
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 1C
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 1D
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6).
Patients are evaluated 1-3 weeks after biopsy.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 1E
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6).
Patients are evaluated 1-3 weeks after biopsy.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 2A
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive no replicate vaccine.
Patients undergo surgical biopsy at replicate vaccine site on day 1.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 2B
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 2C
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 2D
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6).
Patients are evaluated 1-3 weeks after biopsy.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
Experimental: Arm 2E
Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43.
Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6).
Patients are evaluated 1-3 weeks after biopsy.
|
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Given subcutaneously and intradermally
Patients undergo surgical biopsy at replicate vaccine site
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Features of lymphoid neogenesis at the replicate immunization site
Time Frame: Up to Day 85
|
Up to Day 85
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Craig L. Slingluff, MD, University of Virginia
Publications and helpful links
General Publications
- Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL Jr. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 Apr;8(1):e000544. doi: 10.1136/jitc-2020-000544.
- Judge JM, Chianese-Bullock KA, Schroen AT, Slingluff CL Jr. Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clin Trials. 2013 Feb;10(1):143-50. doi: 10.1177/1740774512464438. Epub 2012 Nov 29.
- Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med. 2010 Aug 20;8:79. doi: 10.1186/1479-5876-8-79.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Eye Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Conjunctival Diseases
- Neuroendocrine Tumors
- Nevi and Melanomas
- Eye Neoplasms
- Melanoma
- Conjunctival Neoplasms
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Freund's Adjuvant
Other Study ID Numbers
- 13498
- P30CA044579 (U.S. NIH Grant/Contract)
- R01CA057653 (U.S. NIH Grant/Contract)
- UVACC-MEL-48
- UVACC-IRB-13498
- UVACC-PRC-450-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraocular Melanoma
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...PfizerActive, not recruitingSunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaCiliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCiliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular MelanomaUnited States
-
National Cancer Institute (NCI)CompletedCiliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension MelanomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedLiver Metastases | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Extraocular Extension MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension MelanomaCanada, United States
-
Case Comprehensive Cancer CenterCompletedCiliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Recurrent Intraocular MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension MelanomaUnited States
Clinical Trials on incomplete Freund's adjuvant
-
Immune Response BioPharma, Inc.croUnknownMultiple SclerosisUnited States
-
EpimmuneUnknownLung CancerUnited States
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedRenal Cell CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
National Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedIntraocular Melanoma | Melanoma (Skin)United States
-
Craig L Slingluff, JrNational Cancer Institute (NCI)Completed
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedMelanoma (Skin) | Non-melanomatous Skin CancerUnited States